Incidentno povišena vrijednost tireotropina u inače dobro liječenih hipotireoidnih bolesnika ne zahtijeva povišenje doze levotiroksina by Darko Solter & Miljenko Solter
Acta Clin Croat,  Vol. 53,   No. 3,  2014 291
Acta Clin Croat 2014; 53:291-293 Original Scientific Paper 
InCIdentAlly elevAted thyrOtrOPIn In 
OtherwISe PrOPerly treAted hyPOthyrOId 
PAtIentS dOeS nOt requIre hIgher 
levOthyrOxIne dOSe
darko Solter1 and Miljenko Solter2
1Clinical department of ent, head and neck Surgery, 2department of endocrinology, Sestre milosrdnice 
university hospital Center, Zagreb, Croatia
SuMMAry – In 20 properly treated hypothyroid patients with normal thyrotropin (tSh) va-
lues during previous observation, tSh was incidentally mildly/moderately elevated (4.5-8.0 mIu/l; 
normal values 0.4-4.0) on the last follow up. however, they were continuously treated with the 
same levothyroxine (lt4) dose (mean: 95 µg) and six months later all tSh values normalized. The 
authors suggest that the physicians, in response to incidentally increased tSh value in otherwise 
properly treated hypothyroid patients, refrain from prompt increasing the lt4 dose unless tSh 
values are persistently elevated or/and progressing. 
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Introduction 
treatment of hypothyroidism, although appar-
ently simple, poses challenges and complexities1,2, and 
the search for optimal replacement therapy is still go-
ing on. Serum thyrotropin (tSh) is considered to be 
the most reliable assay for proper treatment follow up, 
however, it has some limitations3,4. The normal values 
of tSh, especially in the upper range, are a matter 
of dispute5. It has been proposed that the upper limit 
of the normal range should be reduced to 2.5 mIu/l 
(usually 4-4.5 mIu/l)6, which is supported by some7,8, 
but opposed by others9,10. This proposal has also been 
challenged by the finding that mildly increased tSh 
in elderly people did not lead to impaired cognition11, 
and could be a proper adaptation phenomenon even 
associated with longevity12. differences between nar-
rower intra-individual and wider inter-individual dis-
tributions of thyroxine (t4)13 and tSh14 could explain 
the origin of the earliest phase of thyroid failure and 
certainly confirm that the distinction between normal 
thyroid function and mild, subclinical hypothyroid-
ism is merely arbitrary13.
In our large series of hypothyroid patients treat-
ed with levothyroxine (lt4) for several years, long 
enough to perform necessary modifications of ther-
apy, 75% had normal tSh, while in others, mildly 
or moderately increased tSh was overwhelmingly 
dominant15. 
In this study, we were especially focused on hypo-
thyroid patients, otherwise properly treated for several 
years, with an incidentally increased tSh value.
Subjects and Methods
The study included 20 middle-aged (average 52 
years) hypothyroid patients treated with lt4 for sev-
eral (mean 2.8) years and examined between July 2011 
and June 2012. This group accounted for about 10% of 
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the total number of hypothyroid patients treated by 
one of the authors (M.S.) in that period. They were 
properly treated with normal tSh value, except for 
a single mildly/moderately increased value on the last 
follow up. Serum values of t4 and triiodothyronine 
(t3) were normal.
Results
twenty hypothyroid patients, previously prop-
erly treated, showed increased serum tSh (4.5-8.0 
mIu/l; normal values: 0.4-4.0- value 1) on the last 
follow up. They were continuously treated with the 
same lt4 dose (mean 95.0 µg) and six months later 
tSh values (value 2) unexceptionally normalized 
(Fig. 1). 
Discussion
we demonstrated that the incidentally elevated 
tSh in previously properly treated hypothyroid pa-
tients normalized without increasing the lt4 dose. 
Obviously, a vice versa situation is as possible. This 
supports our previous statement that in the majority 
of hypothyroid patients with mildly or moderately ele-
vated tSh, the lt4 dose could remain unchanged15.
Proper compliance in these patients was carefully 
tested by a short questionnaire and direct physician-
patient communication. Furthermore, there was no 
reason to suspect suddenly occurring lt4 absorp-
tion problems. we believe that, rather than flaws in 
the adherence to lt4, or malabsorption, intra-indi-
vidual variations in tSh suppressibility could be re-
sponsible. These variations are wider in hypothyroid 
patients, even if properly treated, than in healthy 
subjects, reflecting impairment in the tSh-thyroid 
hormone feedback control in hypothyroidism (un-
published data). The results point to the limitations 
of tSh alone being an adequate measure for thyroid 
hormone-controlled homeostasis in hypothyroid pa-
tients treated with lt4 and confirm the growing need 
of personalized replacement therapy14,16.
we advise that the physicians, facing an inciden-
tally increased tSh value, refrain from promptly 
increasing lt4 dose, unless tSh values are persis-
tently elevated or/and progressing. Such an aggressive 
increase in lt4 dose could result in over-suppressed, 
or, at least, low normal tSh, which have been both 
reported to be associated with atrial fibrillation in the 
elderly17,18.
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Sažetak
InCIdentnO POvIšenA vrIJednOSt tIreOtrOPInA u InAče dOBrO lIJečenIh 
hIPOtIreOIdnIh BOleSnIKA ne ZAhtIJevA POvIšenJe dOZe levOtIrOKSInA
D. Solter i M. Solter
Kod 20 hipotireoidnih bolesnika koji su prethodno dobro liječeni uz uredne vrijednosti tireotropina (tSh) na po-
sljednjoj kontroli nađena je blago do umjereno povišena vrijednost tSh (4,5-8,0 mIu/l: n.v. 0,4-4,0). Ipak je nastavljeno 
liječenje istom dozom levotiroksina (lt4), u prosjeku 95 µg, a nakon 6 mjeseci vrijednosti tSh su se normalizirale. Autori 
preporučuju da se liječnik suočen s incidentno povišenom vrijednošću tSh u inače dobro liječenih hipotireoidnih bole-
snika suzdrži od povišenja doze lt4 ako vrijednost tSh nije trajno povišena i/ili u progresiji.
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